AZD1480
$100.00 – $1,000.00
Conditions of optimal FVII and FVIIa Proteins performance should be determined experimentally by the investigator.
- Details & Specifications
- References
- More Offers
| Catalog No. | APIM050092 |
|---|---|
| Product Name | AZD1480 |
Description
Background Information:
AZD1480 is a potent, selective and orally active ATP-competitive inhibitor of JAK1 and JAK2 with IC?? of 1.3 nM and 0.26 nM, respectively. Inhibits signaling and proliferation of Jak2 V617F cell lines in vitro, demonstrates in vivo efficacy in a TEL-Jak2 model, and potently blocks Stat3 signaling and Ontogenesis in solid tumors, currently in clinical trials.
Reference:
1. M. Hedvat, et al., The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors, Cancer Cell, Vol.16 (6), 487-497, 8 Dec. 2009.
2. A. Scuto, et al., The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival, Leukemia, 2011 Mar; 25(3):538-50.
3. S. Ioannidis, et al., J. Med. Chem. 2011, 54, 262–276.
APIM050092: AZD1480
CAS No.: 935666-88-9.
Molecular Formula: C14H14ClFN8.
Molecular Weight: 348.8.
Purity: >99.5% Chem and optical purity (HPLC and Chiral HPLC).
QC: HPLC-MS, 1HNMR, Chiral HPLC, and Quantitative Elemental Analysis.
Solubility: Soluble in DMSO.
Storage: Store at 0°C (short term), -20°C (long term), desiccated.
